Relief of pain & inflammation in - osteoarthritis, rheumatoid arthritis, other chronic musculoskeletal disorders, acute gout, dysmenorrhoea, & following dental surgery.
Etoricoxib is a potent, orally active cyclooxygenase-2 (COX-2) specific inhibitor within, and significantly above, the clinical dose range. Two isoforms of cyclooxygenase have been identified: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is responsible for prostaglandin-mediated normal physiologic functions such as gastric cytoprotection and platelet aggregation. Inhibition of COX-1 by nonselective NSAIDs has been associated with gastric damage and inhibition of platelet aggregation. COX-2 has been shown to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. Selective inhibition of COX-2 by etoricoxib (within the clinical dose range) decreases these clinical signs and symptoms with decreased potential for Gl toxicity and effects on platelet aggregation. Etoricoxib produced dose-dependent inhibition of COX-2 without inhibition of COX-1 at doses up to 150 mg daily. Etoricoxib did not inhibit gastric prostaglandin synthesis.
Adult & adolescent over 16 years: osteoarthritis, chronic musculoskeletal disorders & dysmenorrhoea: 60 mg, once daily, rheumatoid arthritis: 90 mg, once daily, pain following dental surgery & acute gout: 120 mg, once daily.
With medicine:
Oral anticoagulants: In subjects stabilized on chronic warfarin therapy, the administration of Etoricoxib was associated with an increase in prothrombin time.
Diuretics, ACE inhibitors and Angiotensin II Antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs.
Acetylsalicylic Acid: Etoricoxib can be used concomitantly with acetylsalicylic acid at doses used for cardiovascular prophylaxis (low-dose acetylsalicylic acid).
Ciclosporin and tacrolimus: Although this interaction has not been studied with Etoricoxib, coadministration of ciclosporin or tacrolimus with any NSAID may increase the nephrotoxic effect of ciclosporin or tacrolimus.
Lithium: NSAIDs decrease lithium renal excretion and therefore increase lithium plasma levels.
With food & others: Take without regards to meals.
Known hypersensitivity to Etoricoxib, patients with active peptic ulceration or gastrointestinal (GI) bleeding, patients who have developed signs of asthma, acute rhinitis, nasal polyps, angioneurotic oedema or urticaria following the administration of acetylsalicylic acid or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), patient having inflammatory bowel disease, severe congestive heart failure, to children & adolescents under 16 years of age.
Dry mouth, taste disturbance, mouth ulcers, flatulence, constipation, appetite & weight changes, chest pain, fatigue, paraesthesia, influenza-like syndrome & myalgia.
It should be avoided in late pregnancy because it may cause premature closure of the ductus
Administration of single doses of Etoricoxib up to 500 mg and multiple doses up to 150 mg/day for 21 days did not result in significant toxicity. In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the Gl tract, employ clinical monitoring, and institute supportive therapy, if required.
Store at a temperature of below 30°C, protect from light & moisture. Keep out of reach of children.
.png&w=384&q=75)